- Home
- IFRX vs XPL Comparison
IFRX vs XPL Comparison
Compare IFRX & XPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- XPL
- Stock Information
- Founded
- IFRX 2007
- XPL 1984
- Country
- IFRX Germany
- XPL United States
- Employees
- IFRX N/A
- XPL N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- XPL Precious Metals
- Sector
- IFRX Health Care
- XPL Basic Materials
- Exchange
- IFRX Nasdaq
- XPL Nasdaq
- Market Cap
- IFRX 53.5M
- XPL 47.9M
- IPO Year
- IFRX 2017
- XPL N/A
- Fundamental
- Price
- IFRX $1.60
- XPL $0.76
- Analyst Decision
- IFRX Strong Buy
- XPL Strong Buy
- Analyst Count
- IFRX 4
- XPL 2
- Target Price
- IFRX $7.75
- XPL $1.20
- AVG Volume (30 Days)
- IFRX 577.2K
- XPL 110.5K
- Earning Date
- IFRX 08-07-2025
- XPL 08-06-2025
- Dividend Yield
- IFRX N/A
- XPL N/A
- EPS Growth
- IFRX N/A
- XPL N/A
- EPS
- IFRX N/A
- XPL N/A
- Revenue
- IFRX $191,224.00
- XPL N/A
- Revenue This Year
- IFRX N/A
- XPL N/A
- Revenue Next Year
- IFRX $1,336.36
- XPL N/A
- P/E Ratio
- IFRX N/A
- XPL N/A
- Revenue Growth
- IFRX 54.36
- XPL N/A
- 52 Week Low
- IFRX $0.71
- XPL $0.54
- 52 Week High
- IFRX $2.82
- XPL $0.87
- Technical
- Relative Strength Index (RSI)
- IFRX 89.35
- XPL 55.41
- Support Level
- IFRX $0.82
- XPL $0.73
- Resistance Level
- IFRX $0.96
- XPL $0.81
- Average True Range (ATR)
- IFRX 0.11
- XPL 0.04
- MACD
- IFRX 0.06
- XPL -0.00
- Stochastic Oscillator
- IFRX 100.00
- XPL 53.25
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About XPL Solitario Resources Corp.
Solitario Resources Corp is exploration company engaging in acquiring, exploring, and developing zinc properties and other precious metals in safe jurisdictions in North and South America. It has joint venture interests in large, high-grade zinc development projects. The Florida Canyon Zinc Project in Peru is a development asset held jointly with Nexa Resources S.A., Golden Crest Project in South Dakota and the Lik Zinc Project represents a large-tonnage, high-grade development project in Alaska in partnership with Teck Resources. In addition, the company has an additional portfolio of exploration properties and royalties in the Americas.